Gilead Sciences Inc. (GILD): Price and Financial Metrics


Gilead Sciences Inc. (GILD): $67.81

-1.26 (-1.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GILD to Watchlist
Sign Up

Industry: Biotech


Ranked

of 462

in industry

GILD POWR Grades


  • Value is the dimension where GILD ranks best; there it ranks ahead of 99.22% of US stocks.
  • GILD's strongest trending metric is Growth; it's been moving down over the last 161 days.
  • GILD's current lowest rank is in the Momentum metric (where it is better than 4.06% of US stocks).

GILD Stock Summary

  • Gilead Sciences Inc's market capitalization of $88,346,231,454 is ahead of 97.01% of US-listed equities.
  • Over the past twelve months, GILD has reported earnings growth of 277.75%, putting it ahead of 92.3% of US stocks in our set.
  • The volatility of Gilead Sciences Inc's share price is greater than that of just 2.85% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Gilead Sciences Inc are EW, ADI, LRCX, BDX, and KLAC.
  • Visit GILD's SEC page to see the company's official filings. To visit the company's web site, go to www.gilead.com.

GILD Valuation Summary

  • GILD's price/sales ratio is 3.4; this is 10.53% lower than that of the median Healthcare stock.
  • GILD's price/sales ratio has moved down 24.1 over the prior 243 months.
  • Over the past 243 months, GILD's price/sales ratio has gone down 24.1.

Below are key valuation metrics over time for GILD.

Stock Date P/S P/B P/E EV/EBIT
GILD 2021-08-31 3.4 4.6 17.7 15.0
GILD 2021-08-30 3.4 4.6 17.5 14.9
GILD 2021-08-27 3.4 4.5 17.3 14.8
GILD 2021-08-26 3.4 4.5 17.3 14.8
GILD 2021-08-25 3.4 4.5 17.3 14.8
GILD 2021-08-24 3.4 4.6 17.5 14.9

GILD Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at -50.73%.
  • Its 5 year cash and equivalents growth rate is now at -21.79%.
  • Its 4 year net income to common stockholders growth rate is now at -71.39%.
GILD's revenue has moved up $5,355,000,000 over the prior 33 months.

The table below shows GILD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 27,482 10,095 7,394
2021-06-30 26,638 9,092 5,162
2021-03-31 25,564 9,342 301
2020-12-31 24,689 8,168 123
2020-09-30 23,147 8,832 1,268
2020-06-30 22,174 9,481 -257

GILD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GILD has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
  • GILD's asset turnover comes in at 0.406 -- ranking 114th of 682 Pharmaceutical Products stocks.
  • ENTA, RDUS, and ADMS are the stocks whose asset turnover ratios are most correlated with GILD.

The table below shows GILD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.406 0.805 0.259
2021-06-30 0.402 0.801 0.179
2021-03-31 0.405 0.806 0.066
2020-12-31 0.403 0.815 0.058
2020-09-30 0.389 0.790 0.058
2020-06-30 0.375 0.786 0.009

GILD Price Target

For more insight on analysts targets of GILD, see our GILD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.84 Average Broker Recommendation 1.7 (Moderate Buy)

GILD Stock Price Chart Interactive Chart >

Price chart for GILD

GILD Price/Volume Stats

Current price $67.81 52-week high $74.12
Prev. close $69.07 52-week low $61.39
Day low $67.77 Volume 8,638,406
Day high $69.31 Avg. volume 7,930,292
50-day MA $70.47 Dividend yield 4.11%
200-day MA $68.87 Market Cap 85.06B

Gilead Sciences Inc. (GILD) Company Bio


Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases. Daniel O’Day has been Gilead Science’s Chief Executive Officer since March of 2019 and the company is headquartered in Foster City, California. With over 10,000 employees worldwide, the company has operations in North America, Asia, the Middle East and Europe. As of 2019, the company had global sales of $22.1 billion. Some of Gilead Science’s major competitors are Novo Nordisk A/S ADR (NVO), Biogen Inc. (BIIB), and Novartis AG ADR (NVS).


GILD Latest News Stream


Event/Time News Detail
Loading, please wait...

GILD Latest Social Stream


Loading social stream, please wait...

View Full GILD Social Stream

Latest GILD News From Around the Web

Below are the latest news stories about Gilead Sciences Inc that investors may wish to consider to help them evaluate GILD as an investment opportunity.

Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs

Gilead Sciences Inc (NASDAQ: GILD ) said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV treatments over the last two years. The alleged scheme was reported earlier by The Wall Street Journal . The Company found 85,247 bottles tampered with or faked, including versions of its Biktarvy and Descovy treatments. Gilead said it had seized Full story available on Benzinga.com

Benzinga | January 19, 2022

Beech Hill Advisors, Inc. Buys Block Inc, The Walt Disney Co, Activision Blizzard Inc, Sells ...

New York, NY, based Investment company Beech Hill Advisors, Inc. (Current Portfolio) buys Block Inc, The Walt Disney Co, Activision Blizzard Inc, Crown Castle International Corp, Gilead Sciences Inc, sells Delta Air Lines Inc, Broadcom Inc, L3Harris Technologies Inc, Exact Sciences Corp, Chewy Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Beech Hill Advisors, Inc..

Yahoo | January 19, 2022

UPDATE 2-Gilead says counterfeit HIV drugs ended up with patients

Gilead Sciences Inc said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV treatments over the last two years, endangering patients. The drugmaker said it found 85,247 bottles that had been tampered with or faked, including versions of its Biktarvy and Descovy treatments. In a separate statement on Wednesday, Gilead said it has seized the bottles of Gilead-labeled medication from 17 locations in nine states as part of its investigation.

Yahoo | January 19, 2022

Gilead Sciences (GILD) Receives a Hold from Morgan Stanley

In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price target of $72.00. The company's shares closed last Tuesday at $70.47. According to TipRanks.com, Harrison is a 5-star analyst with an average return of 11.1% and a 53.2% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Zentalis Pharmaceuticals, and BioMarin Pharmaceutical. Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $77.29, an 8.2% upside from current levels.

Catie Powers on TipRanks | January 18, 2022

Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US

Gilead Sciences Inc (NASDAQ: GILD ) recently notified the FDA of its decision to voluntarily withdraw the use of Zydelig for two types of blood cancer, including follicular lymphoma (FL) and small lymphocytic leukemia (SLL). In 2014, the FDA granted accelerated approval to treat relapsed follicular B-cell non-Hodgkin lymphoma and relapsed small lymphocytic leukemia, … Full story available on Benzinga.com

Benzinga | January 18, 2022

Read More 'GILD' Stories Here

GILD Price Returns

1-mo -5.61%
3-mo 1.87%
6-mo 0.25%
1-year 4.00%
3-year 10.45%
5-year 14.25%
YTD -6.61%
2021 29.95%
2020 -6.70%
2019 7.88%
2018 -9.92%
2017 2.96%

GILD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GILD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8558 seconds.